Skip to main content
Figure 1 | Lipids in Health and Disease

Figure 1

From: Low incidence of paradoxical reductions in HDL-C levels in dyslipidemic patients treated with fenofibrate alone or in combination with ezetimibe or ezetimibe/simvastatin

Figure 1

Distribution in mean percent. Distribution in mean percent changes from baseline in HDL-C for patients in the placebo group (n = 123) (A); fenofibrate 160 mg group (n = 368) (B); ezetimibe 10 mg plus fenofibrate 160 mg group (n = 183) (C); and ezetimibe/simvastatin 10/20 mg plus fenofibrate 160 mg group (n = 180) (D)

Back to article page

Lipids in Health and Disease

ISSN: 1476-511X